课题基金 / 基金详情

Neuron regenerative therapeutic, NNI-362, for first-in-human safety and PK for AD

Neuron regenerative therapeutic, NNI-362, for first-in-human safety and PK for AD
神经元再生治疗药物 NNI-362,首次在人类中实现 AD 安全性和 PK
批准号:
9912573
负责人:
JUDITH A KELLEHER-ANDERSSON
金额:
$26.35万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2018
资助国家:
美国
项目状态:
已结题
起止时间:
2018-09-01 至 2021-12-31

项目摘要

项目成果

JUDITH A KELLEHER-ANDERSSON的其他基金

相关文献

中文摘要
翻译
项目总结/摘要 对于大约530万美国人来说, 被认为已经患有阿尔茨海默病(AD)。十年的失败, 单独使用神经保护剂,Neuronascent发现并开发了一种治疗方法, 不仅能阻止进一步的神经元损失和功能障碍, 神经元存活到成熟,取代那些失去的。这种神经再生剂 应该可以阻止甚至逆转阿尔茨海默氏症患者的记忆障碍。 Neuronascent的目标是向FDA提交NNI-362治疗阿尔茨海默病的IND, 完成IND申请后。NIA支持FDA要求的GLP 安全性研究表明,在IND前会议后, FDA.根据这项资助计划,Neuronascent将寻求监管机构的帮助, 承包商提交IND申请,其中包括评估该临床计划的临床计划 NCE在健康老年人群中的安全性。在获得FDA批准后, 作为NNI-362治疗阿尔茨海默病的首次人体试验,Neuronascent旨在确定 在50-72岁健康志愿者中的安全性、耐受性和PK。男女 志愿者将以三种递增剂量之一口服单剂量NNI-362 剂量(SAD),有和没有食物。接下来是14天的每日上升期 剂量(MAD)试验。将评估NNI-362的血浆水平,以确定 药代动力学和是否达到潜在的有效剂量。如果NNI-362 被认为是安全和耐受性良好的,然后可以测试该药物促进 海马中的新神经元(vMRI)和停止或逆转痴呆和受损 在阿尔茨海默病患者中的功能,在扩大的安全性和有效性试验中。神经细胞增生症 一种新的神经元再生治疗方法针对衰老,这是最大的风险因素, 阿尔茨海默氏症和海马神经退行性病变导致体积损失, 与老年痴呆症相关。
英文摘要
Project Summary/Abstract There is only temporary, symptomatic relief for the approximately 5.3 million Americans thought to already suffer from Alzheimer's disease (AD). With a decade of failures for neuroprotective agents alone, Neuronascent discovered and developed a therapy that would not just stop further neuron loss and dysfunction, but that would promote new neurons that survive to maturation, replacing those lost. This neuron regenerative agent should then halt or even reverse the memory impairment in Alzheimer's patients. Neuronascent aims to submit an IND to the FDA for NNI-362 for Alzheimer's disease, following completion of the IND application. The NIA supported the FDA-required GLP safety studies showing the agent to also be safe, following a pre-IND meeting with the FDA. Neuronascent, under this granting program, will enlist the help of regulatory contractors to submit an IND application that includes a Clinical plan that assesses this NCE for its safety in a healthy aged population. On obtaining FDA approval to initiate the first-in-human testing of NNI-362 for Alzheimer's disease, Neuronascent aims to determine the safety, tolerability and PK in a healthy volunteers aged 50-72. Male and female volunteers will be administered a single dose of NNI-362 orally at one of three ascending doses (SAD) , with and without food. This will be followed by a 14-day daily ascending dose (MAD) test. Plasma levels of NNI-362 will be assessed to determine pharmacokinetics and whether a potential efficacious dose has been reached. If NNI-362 is deemed safe and well-tolerated, the agent could then be tested for ability to promote new neurons in the hippocampus (vMRI) and halt or reverse dementia and impaired function in Alzheimer's patients, in expanded safety and efficacy trials. Neuronascent's novel neuron regenerative therapeutic targets aging, which is the greatest risk-factor for Alzheimer's, and hippocampal neurodegeneration causing volume loss, that is directly correlated with dementia in Alzheimer's disease.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Completion of Non-clinical long-term GLP safety and GMP manufacture for first-in-class neuron regenerative therapy, NNI-362 Phase 2 POC AD trial
  • 批准号:
    10710666
  • 项目类别:
  • 资助金额:
    $210.0万
  • 财政年份:
    2023
  • 负责人:
    JUDITH A KELLEHER-ANDERSSON
  • 依托单位:
Neuron regenerative therapeutic, NNI-362, for first-in-human safety and PK for AD
  • 批准号:
    10349352
  • 项目类别:
  • 资助金额:
    $24.66万
  • 财政年份:
    2018
  • 负责人:
    JUDITH A KELLEHER-ANDERSSON
  • 依托单位: